Prudence B. Lam, MD

Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center
Phone: (617) 497-9646
Fax: (617) 499-5464


PLam1@caregroup.harvard.edu

Prudence B. Lam, MD

Beth Israel Deaconess Medical Center

EDUCATIONAL TITLES

  • Instructor, Medicine, Harvard Medical School
  • Physician-Investigator, Cancer Biology Program, Beth Israel Deaconess Medical Center

DF/HCC PROGRAM AFFILIATION

Research Abstract

My clinical interest is currently in the field of cancer genetics and cancer prevention. Previously my research focus was on the language used in recruiting underserved minorities into clinical trials, their attitudes toward these studies, and how these may impact their participation. Through my translational laboratory research in Her2 overexpressing breast cancer, I also have a keen interest in cell signaling, especially downstream of oncogenic Ras and Her2/Neu. I would like to examine the relative effects and efficacy of targeted agents on various ethnic populations with epithelial cancers. Learning more about this would be extremely beneficial in better tailoring our treatments for these individuals.

Publications

Powered by Harvard Catalyst
  • Lam PB,Burga LN,Wu BP,Hofstatter EW,Lu KP,Wulf GM. Prolyl isomerase Pin1 is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stability. Mol Cancer 2008; 7:91. PubMed
  • Lam P, Berman S, Thurer R, Ashiku S, Decamp M, Goldstein M, Schumer S, Halmos B, Karp D, Coute D, Bergman M, Boyd-Sirard C, Ou SH, Muzikansky A, Woodard C, Huberman M. Phase II Trial of Sequential Chemotherapy Followed by Chemoradiation, Surgery, and Postoperative Chemotherapy for the Treatment of Stage IIIA/IIIB Non-Small-Cell Lung Cancer. Clin Lung Cancer 2006; 8:122-9. PubMed
  • Lam PB, Vacek PM, Geller BM, Muss HB. The association of increased weight, body mass index, and tissue density with the risk of breast carcinoma in Vermont. Cancer 2000; 89:369-75. PubMed